Exact Sciences Corporation announced the publication of a new modeling study in the Journal of the National Cancer Institute evaluating the benefit-to-burden ratios of established and emerging colorectal cancer screening strategies. The study found that Cologuard Plus™, a next-generation multitarget stool DNA (mt-sDNA) test, was the only noninvasive screening option shown to be efficient at guideline-recommended intervals and age ranges for average-risk adults starting at age 45. The analysis, based on the CRC-AIM microsimulation platform and methodologies adopted by the United States Preventive Services Task Force, incorporated updated clinical data and was sponsored by Exact Sciences. The results of the study have been published and are now available.